Sun Pharmaceutical Limited Q4 results show revenue fell from 11414.85 to 11303.95 crores, a 0.97% decrease in growth. EPS also dropped from ₹9 to ₹8.3, down by 7.78%.
First, Let’s Begin with Quarter-on-Quarter Basis:
Sun Pharmaceutical Ltd. shared its Q4 results on Tuesday. They earned 11303.95 crores in revenue this quarter, but that’s less than the 11414.85 crores they made last quarter. Unfortunately, the company’s growth decreased by 0.97 percent when comparing the two quarters.
In terms of profits, Nimbark Ltd’s PAT (Profit After Tax) for this quarter was 2016.78 crores, down from 2188.04 crores in the previous quarter. Their quarter-to-quarter growth declined by 7.83 percent.
The company’s EPS (Earnings Per Share) this quarter is ₹8.3, which is a decrease of 7.78% from the ₹9 EPS in the previous quarter.
Also read: ☞ ” Barbeque Nation Q4FY23 Results: Consolidated PAT Slips to Rs 11.8 Cr “
Now, Let’s Analyze the Results on a Year-over-Year Basis:
The company made a total revenue of 44520.20 crores this year (2023), which is 12.49 percent higher than last year’s total revenue of 39576 crores.
This year’s PAT (Profit After Tax) is 8560.84 crores, which is also 151.36% higher than last year’s PAT of 3405.82 crores.
The EPS (Earnings Per Share) for this year is ₹35.3, which is 159.56% more than the EPS of ₹13.6 earned last year.
Sun Pharmaceutical Share Dividend Announcement / Record Date:
The Board of Directors has declared a Final Dividend of ₹4 per Equity Share of Face Value of ₹1 each of the Company (400% of Face Value). Total Dividend for FY23 stood at ₹10.50 per Equity Share (Interim Dividend of ₹1 per Equity Share)
| Dividend | Record Date |
| ₹4 per Equity Share | Coming Soon |
The record date for the dividend has not arrived yet.
About Sun Pharmaceutical:
Sun Pharmaceutical Industries Limited, with its headquarters in Mumbai, is a multinational pharmaceutical company from India. It specializes in the production and distribution of pharmaceutical formulations and active pharmaceutical ingredients, serving over 100 countries worldwide.
Download the Full PDF of Q4 Results: Click Here
For more of the Latest News, Click Here
One thought on “Sun Pharmaceutical Q4FY23 Results: Consolidated PAT of Rs 2016.78 Cr”